For Research Use Only. Not for Clinical Use.

To overcome the limitation of the short circulating half-life of small biotherapeutics, a large variety of half-life extension strategies have emerged in the last decades. The albumin-binding domain antibody (AlbudAb) was widely used to extend the half-lives of short-lived drugs. Creative Biolabs is very specialized in AlbudAb based half-life extension field. We will spare no effort to provide high-quality half-life extension services to help your project go efficiently and smoothly.

Introduction of AlbudAb

Advanced protein engineering has greatly facilitated the development of the AlbudAb, a human domain antibody (dAb) that combines with human serum albumin. Domain antibodies are highly stable, and they are the smallest functional binding units of human immunoglobulins that contain only a single heavy or light chain variable domain.

Fig.1 Schematic model of AlbudAb technology. (JBowen, 2015)

Multiple Functions of AlbudAb

The AlbudAbs are already utilized to prolong the half-lives of multiple drugs. For example, a fusion protein joining an AlbudAb to exendin-4, a short-duration peptide, has been completed. Following subcutaneous injection, an AlbudAb binds reversibly to albumin to achieve prolonged systemic exposure. The AlbudAbs can potentially be applied to generate a range of long-acting biopharmaceuticals. In addition, AlbudAbs could potentially be used to generate numerous long half-life versions of many short-lived drugs to improve their dosing regimen. Moreover, AlbudAbs have also been proved to increase the half-life of therapeutic molecules via an alternative half-life extension technology utilizing a serum albumin-binding domain antibody genetically fused to the target molecules.

The antibody can be fused with therapeutic proteins or polypeptide drugs such as short peptide molecules, antibody molecules, antibody fragments, cytokines, interferons, tumor necrosis factor, tumor marker molecules, and the product has a prolonged drug half-life and improved bioavailability. They should therefore make ideal fusion partners for the creation of therapeutic proteins with long serum half-lives.

AlbudAb Based Half-Life Extension Services

In recent years, we have completed many cases of albudAb based half-life extension and accumulated rich experience in the process of practice. We can provide a variety of services of half-life extension services, such as AlbudAbs fused with therapeutic proteins or polypeptide drugs, short peptide molecules, cytokines interferons, tumor necrosis factor, and tumor marker molecules. AlbudAbs are characterized by good specificity, higher affinity, and stability, and the AlbudAbs can effectively prolong the half-life of the biological drugs. We will select a suitable method according to the molecular characteristics used in your project.

Highlights of AlbudAb Based Half-Life Extension Services

• Advanced technology platform
• Rich experience in the development of AlbudAbs fused with therapeutic proteins or polypeptide drugs
• Customizable services for your project
• Short cycle time

If you are interested in our AlbudAb based half-life extension services, please contact us for more details.

Reference

1. Bowen, C. L.;et al.Utilizing LC-MS/MS to provide adaptable clinical bioanalytical support for an extended half-life bioactive peptide fused to an albumin-binding domain antibody. Analytical Methods.2015, 7(1): 237-243.